An experimental drug for Crohn’s disease is showing encouraging results in an early trial, sending many patients into remission and keeping them there for 12 weeks or more. The compound, called mongersen, is a pill that shuts down inflammation in the gut.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.